Pulmonx Stock

Pulmonx Equity

The The Equity of Pulmonx (LUNG) as of Aug 20, 2026 is 54.12 M USD. In the previous year, The Equity was 85.81 M USD — a change of -36.93% (lower).

Equity

54.12 MUSD

YoY

-36.93%

Last updated:

In 2026, Pulmonx's equity was 54.12 M USD, a -36.93% increase from the 85.81 M USD equity in the previous year.

Access this data via the Eulerpool API

Pulmonx Stock analysis

What does Pulmonx do? Pulmonx Corp is an innovative medical technology company based in the USA and Europe. The company specializes in the development of non-invasive solutions for the treatment of lung diseases. Pulmonx was founded in 1997 and has since introduced numerous groundbreaking technologies to the market that improve the quality of life for patients with chronic lung diseases. Pulmonx is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Pulmonx's Equity

Pulmonx's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Pulmonx's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Pulmonx's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Pulmonx's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Pulmonx’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Pulmonx stock

The Equity of Pulmonx is 54.12 M USD in 2026.

The Equity of Pulmonx changed from 85.81 M USD to 54.12 M USD, representing a -36.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Pulmonx since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Pulmonx historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Pulmonx

All Key Metrics — Pulmonx